New diabetes drug tested in everyday clinics
NCT ID NCT07433192
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is observing 300 adults with type 2 diabetes who are already taking luseogliflozin as part of their routine care. Researchers will track changes in blood sugar levels, body weight, and side effects over time. The goal is to see how well the drug works in real-world settings, outside of strict research conditions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
luseogliflozin (a diabetes drug that helps lower blood sugar by making the kidneys remove more sugar in urine)
What this could lead to
If successful, this study could confirm that luseogliflozin works well and is safe for managing type 2 diabetes in everyday medical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is also early-stage and only includes patients already taking the drug, which may limit conclusions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GBUZ hospital
RECRUITINGAnapa, Russia